Thomas Schinecker president of Roche's 454 Life Sciences
This article was originally published in Scrip
Executive Summary
454 Life Sciences, a centre of excellence of Roche's Applied Science business unit, has appointed Dr Thomas Schinecker lifecycle leader for sequencing and president effective from 1 August, reporting to Robert Yates, head of Applied Science. Dr Schinecker currently serves Roche as diagnostics general manager of Sweden.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.